CD274 and neoplasm: In a PTCL mouse xenograft model, tumor growth inhibition following alisertib treatment was only approximately 30%, while anti-PD-L1 monotherapy was ineffective; however, alisertib combined with anti-PD-L1 treatment resulted in >90% growth inhibition, indicative of a synthetic lethal interaction.